Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A) + Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Magnetic Resonance Angiography
Conditions
Magnetic Resonance Angiography, Peripheral Vascular Diseases, Peripheral Arterial Diseases
Trial Timeline
Jul 1, 2004 → Oct 1, 2004
NCT ID
NCT00652418About Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A) + Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)
Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A) + Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A) is a phase 2 stage product being developed by Bayer for Magnetic Resonance Angiography. The current trial status is completed. This product is registered under clinical trial identifier NCT00652418. Target conditions include Magnetic Resonance Angiography, Peripheral Vascular Diseases, Peripheral Arterial Diseases.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00652418 | Phase 2 | Completed |
Competing Products
20 competing products in Magnetic Resonance Angiography